Analysis of lung cancer diagnosis and management in clinical practice
Landsteiner Lung Cancer Research Platform (LALUCA) A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
This study is trying to see how lung cancer is diagnosed and treated in everyday medical settings to improve care by focusing on genetic testing and treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 125 Years |
| Sex | All |
| Sponsor | Karl Landsteiner Institute for Lung Research and Pneumological Oncology Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT04733430 on ClinicalTrials.gov |
What this trial studies
This project involves a prospective analysis of lung cancer diagnosis and treatment in real-world settings. It aims to establish a clinical platform for collecting data on molecular testing, treatment sequences, and disease progression in lung cancer patients. A key focus is on molecular biomarker testing and next-generation sequencing (NGS) to identify druggable mutations that can improve patient outcomes. The collected data will help assess the current state of lung cancer care and identify areas for improvement.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed lung cancer who can provide informed consent.
Not a fit: Patients without a confirmed diagnosis of lung cancer or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this project could enhance the quality of care and treatment outcomes for lung cancer patients by providing insights into effective diagnostic and therapeutic strategies.
How similar studies have performed: Other studies focusing on molecular testing and NGS in lung cancer have shown promising results, indicating that this approach is supported by previous successful research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent * Histologically confirmed lung cancer * Age ≥ 18 years * Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments Exclusion Criteria: \-
Where this trial is running
Vienna
- Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie — Vienna, Austria (Recruiting)
Study contacts
- Principal investigator: Georg-Christian Funk, MD — 2nd Medical Department with Pneumology
- Study coordinator: Georg-Christian Funk, MD
- Email: georg-christian.funk@gesundheitsverbund.at
- Phone: +43 1 4000-2203
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.